Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.68 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959825 | 0.90 | MAPT (0.71) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL2963606 | 0.89 | MAPT (0.55) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL810705 | 0.84 | PDE7A (0.65) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL810183 | 0.84 | MAPT (0.64) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL810413 | 0.84 | MAPT (0.53) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL2018194 | 0.84 | ALDH1A1 (0.67) | PDE7AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2960443 | 0.84 | PDE7A (0.71) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL2962044 | 0.83 | GSTP1 (0.61) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL19048971 | 0.83 | PDE7A (0.71) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL25250134 | 0.83 | PDE7A (0.66) | PDE7APDE7BMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2013130958-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7323458-B1 | Dihydrobenzodiazepins and their use for treating dyslipidemia | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-01-29 | — | — | US | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE7A 4223/4885PDE7B 4176/4885MAPT 1347/4885 |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | PDE7A 1086/4885PDE7B 1250/4885MAPT 4609/4885 |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE7A 4223/4885PDE7B 4176/4885MAPT 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.